Oxford BioDynamics (LON:OBD) Trading Up 2.2% – Here’s What Happened

Oxford BioDynamics Plc (LON:OBD) shot up 2.2% on Monday . The stock traded as high as GBX 0.16 and last traded at GBX 0.14. Approximately 34,958,953 shares changed hands during trading, an increase of 140% from the average session volume of 14,572,708 shares. The stock had previously closed at GBX 0.14.

Oxford BioDynamics Stock Performance

The company’s 50 day moving average is GBX 0.19 and its 200-day moving average is GBX 0.23. The company has a current ratio of 0.88, a quick ratio of 2.80 and a debt-to-equity ratio of 457.97. The company has a market capitalization of £4.29 million, a P/E ratio of -0.12 and a beta of 0.42.

Oxford BioDynamics (LON:OBD) last posted its quarterly earnings data on Tuesday, June 30th. The biotechnology company reported GBX (0.10) earnings per share (EPS) for the quarter. The business had revenue of GBX 69 million during the quarter. Oxford BioDynamics had a negative return on equity of 316.67% and a negative net margin of 1,018.54%.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.